

Overview of CML related sessions at EHA2025 Congress

June 12-15, 2025 in Milan

Time slots	Sessions
CML sessions	
<p>June 12 (Thursday)</p> <p>8.00 – 9.30 CEST</p> <p>Room: Coral 7</p>	<p>Satellite Symposium: (Supported by Novartis) From insights to innovations: advancing treatment strategies in chronic myeloid leukemia (CML)</p> <p>Chair: Massimo Breccia (Italy)</p> <p>Program:</p> <ul style="list-style-type: none"> • Recent advances in CML treatment and patient outcomes (M. Breccia, Italy) • Redefining treatment goals: improving efficacy and enhancing tolerability and patient QoL (S. Isfort, Germany) • Navigating treatment challenges: clinical insights into treatment strategies (D. Kim, Canada) • Panel discussion (all faculty)
<p>June 12 (Thursday)</p> <p>15.15 – 16.45 CEST</p> <p>Room: Coral 7</p>	<p>Specialized Working Group Session: Chronic myeloid leukemia and its stem cells</p> <p>Chair: Nick Cross (UK)</p> <p>Program:</p> <ul style="list-style-type: none"> • Modelling stem cell dynamics in CML (R. van Etten, USA) • Insights from single cell analysis of CML stem cells (G. Karlsson, Sweden) • 2025 ELN recommendations on the management of CML (J. Apperley, UK)
<p>June 14 (Saturday)</p> <p>15.45 – 16.45 CEST</p> <p>Room: Auditorium</p>	<p>Hematology-in-Focus Session (Clinical): Chronic myeloid leukemia (CML)</p> <p>Chairs:</p> <ul style="list-style-type: none"> • D. Žáčková (Czech Republic) • G. Sharf (Israel)

Time slots	Sessions
	Program: <ul style="list-style-type: none"> • BCR-ABL1 kinase domain mutations associated with asciminib (S. Soverini, Italy) • Sequencing TKI for optimal management of CML (H. de Lavallade, UK)
Advocacy & Patient Sessions	
June 12 (Thursday) 13.30 – 15.00 CEST Room: Amber Hall 3+4	EHA-Patient Joint Symposium – Session 1 Advancing quality of life as a measurable outcome in clinical trials Chair: Angelo Loris Brunetta (Cyprus) Program: <ul style="list-style-type: none"> • A patient perspective on quality of life (AL Brunetta, Cyprus) • A clinician’s perspective on quality of life (S. Park, France) • Enhancing cancer treatment with PRO data (A. Alanya, Belgium) • A nurse perspective on quality of life (MN Chonghaile, Ireland) • Panel discussion and Q&A (all speakers)
June 12 (Thursday) 15.15 – 16.45 CEST Room: Amber Hall 3-4	EHA-Patient Joint Symposium – Session 2 Evolving endpoint strategies: Navigating new therapies and regulatory acceptance Chairs: <ul style="list-style-type: none"> • Jenica Leah (UK) • Lorenzo Brunetti (Italy) Program: <ul style="list-style-type: none"> • Limitations of traditional endpoints and the need for evolution (J. Leah, UK) • Endpoints: How to align clinical relevance with the lived patient experience (L. Brunetti, Italy) • Endpoints from the perspective of a medicines regulator (F. Pignatti, The Netherlands)

Time slots	Sessions
	<ul style="list-style-type: none"> • An industry perspective on endpoints (J. Ryan, UK) • How can endpoints be improved to support HTA decision making (B. Wieseler, Germany) • Panel discussion and Q&A (all speakers)
Oral Sessions	
<p>June 13 (Friday)</p> <p>17.00 – 18.15 CEST</p> <p>Room: Coral 2</p>	<p>Oral Session: Chronic myeloid leukemia – Clinical Novel approaches of CML treatment</p> <p>Chairs</p> <ul style="list-style-type: none"> • Susanne Saussele (Germany) • Franck Emmanuel Nicolini (France) <p>Program:</p> <ul style="list-style-type: none"> • S165: ENABLE: A PHASE 1A/1B STUDY OF ELVN-001, A SELECTIVE ACTIVE SITE INHIBITOR OF BCR::ABL1, IN PATIENTS WITH PREVIOUSLY TREATED CML (Hochhaus A) • S166: ASCIMINIB (ASC) SHOWS SUPERIOR TOLERABILITY VS NILOTINIB (NIL) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): PRIMARY ENDPOINT RESULTS OF THE PHASE (PH) 3B ASC4START TRIAL (Hochhaus A) • S167: CHRONIC MYELOID LEUKEMIA (CML) TREATMENT DISCONTINUATION AFTER A TWO-STEP DOSE REDUCTION. THE FIRST RESULTS OF THE PHASE 2 STUDY HALF. (Mayer J) • S168: COMPARISON OF MOLECULAR RESPONSE AND SAFETY OF LOWER DOSE (70 MG) VERSUS STANDARD DOSE (100 MG) OF GENERIC DASATINIB IN NEWLY DIAGNOSED PATIENTS WITH CML-CP: RANDOMISED CONTROLLED STUDY FROM INDIA (Satadeve P) • S169: CHARACTERIZATION & EFFICACY OF TERN-701 IN PRE-CLINICAL MODELS OF CHRONIC MYELOID LEUKEMIA (Parsons B)
<p>June 14 (Saturday)</p> <p>17.00 – 18.15</p>	<p>Oral Session: Chronic myeloid leukemia – Biological & translational research Biology of CML treatment response and resistance</p>

Time slots	Sessions
CEST Room: Amber Hall 7+8	Chair: Tomasz Stokłosa (Poland) Program: <ul style="list-style-type: none"> • S160: EARLY RESPONSE PREDICTION BY SINGLE CELL IMMUNE AND SIGNALING PROFILING IN CHRONIC MYELOID LEUKEMIA (Gullaksen SE) • S161: IMPACT OF MITOCHONDRIAL DNA MUTATIONS ON METABOLIC ADAPTATION AND TYROSINE KINASE INHIBITOR RESPONSE IN CHRONIC MYELOID LEUKAEMIA (Pagani I) • S162: INTEGRATING GENOMIC AND TRANSCRIPTOMIC INSIGHTS FOR PREDICTING RESPONSES AND OUTCOMES IN PATIENTS WITH CML RECEIVING 3RD-GENERATION TKI THERAPY (Zhang X) • S163: SETD2 DEFICIENCY IN CML INDUCES METABOLIC REPROGRAMMING CONTRIBUTING TO DRUG RESISTANCE AND DISEASE PROGRESSION (Mancini M) • S164: COMPREHENSIVE MOLECULAR CHARACTERIZATION OF TREATMENT-FREE REMISSION AND RELAPSE IN CML PATIENTS: THE EURO-SKI BIOMARKER STUDY (Rinaldetti S)
Poster presentations	
June 14 (Saturday) 18.30 – 19.30 CEST Poster Hall	Poster Session: Chronic myeloid leukemia – Biology & Translational Research <ul style="list-style-type: none"> • PS1582: GENOTYPING OF SLC22A4 SNP RS460089 IN A REAL-LIFE CML COHORT: IMPLICATIONS FOR IMATINIB RESPONSE AND STABLE DMR ACHIEVEMENT (Machova K) • PS1583: OVERCOMING ASCIMINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA WITH IDENTIFICATION OF THERAPEUTIC STRATEGIES TARGETING BCR::ABL1 MUTATIONS (Okabe S) • PS1584: LOW SERUM IL-8 MAY CONTRIBUTES TO TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (Fujioka Y) • PS1585: GERMLINE VARIANTS IN PEDIATRIC CHRONIC MYELOID LEUKEMIA (Ghete T)

Time slots	Sessions
	<ul style="list-style-type: none"> • PF589: IMMUNOMETABOLIC PROFILING REVEALS TWO TYPES OF METABOLIC DYSFUNCTION IN CLL T CELLS WHICH SHARE MITOCHONDRIAL DEFECTS (Goedhart N) • PF590: NGS STUDY OF PATIENTS WITH A COMBINATION OF CML AND MUTATIONS IN THE JAK2 AND CALR GENES (Kustova D) • PF591: ASCIMINIB EXHIBITS A FAVORABLE CARDIOVASCULAR SAFETY PROFILE - A COMPREHENSIVE IN-VITRO MODEL (Proaktor AG) • PF592: HIGH MIR-202-5P EXPRESSION AT INITIAL DIAGNOSIS AS A PREDICTIVE BIOMARKER FOR TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA-- A RESULT FROM A NESTED CASE-CONTROL STUDY (Nie ZY)
<p>June 14 (Saturday)</p> <p>18.30 – 19.30 CEST</p> <p>Poster Hall</p>	<p>Poster Session: Chronic myeloid leukemia - Clinical</p> <ul style="list-style-type: none"> • PS1586; EARLY PREDICTION OF MR4.5 ATTAINMENT AND SUSTAINED RESPONSE IN CHRONIC MYELOID LEUKEMIA TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG CML212 ROAD TO MR4.5 STUDY (Ono T) • PS1587: PROSPECTIVE VALIDATION OF A DNA/RNA MRD-BASED RISK STRATIFICATION MODEL DURING TWO-PHASE TKI DOSE DE-ESCALATION FOR DISCONTINUATION IN CML (Machova K) • PS1588: IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH ASCIMINIB (ASC) VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS (IS-TKIS) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): ASC4FIRST WK 48 ANALYSIS (Hochhaus A) • PS1589: RESULTS FROM THE FIRST-IN-CHILD PHASE II TRIAL (ITCC-054/COG-AAML1921) OF BOSUTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED (ND) CHRONIC MYELOID LEUKEMIA (CML) (Schellekens K) • PS1590: ASSESSMENT OF TRANSITIONING FROM HIGH-POTENCY TO LOW-POTENCY INHIBITORS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: THE DOWNGRADING-IMPACT (D-IMPACT) PROJECT, A CML CAMPUS STUDY (Bernardi S) • PS1591: THE FRONTLINE SECOND GENERATION TYROSINE KINASE INHIBITORS BRING TREATMENT-FREE REMISSION TO MORE PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Takahashi N) • PS1592: MYELOPROLIFERATIVE NEOPLASMS WITH CONCOMITANT CHRONIC MYELOID

Time slots	Sessions
	<p>LEUKAEMIA ARE ASSOCIATED WITH TKI RESISTANCE AND POOR OUTCOMES: A REVIEW OF 46 CASES (Gagnon LL)</p> <ul style="list-style-type: none"> • PS1593: ASC4OPT STUDY: HIGH EFFICACY AND FAVORABLE TOLERABILITY OF ASCIMINIB ONCE OR TWICE DAILY IN CML PATIENTS WITH SUBOPTIMAL RESPONSE, RESISTANCE OR INTOLERANCE OF 2 OR MORE TYROSINE KINASE INHIBITORS (Hochhaus A) • PS1594: UPDATED RESULTS OF MANAGED-ACCESS PROGRAM (MAP) OF ASCIMINIB USE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN 3 CLINICAL CENTERS. (Chelysheva E) • PS1595: IMPACT OF ADVERSE EVENTS ON QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA (CML) - RESULTS FROM THE PATIENT SURVEY ON HUMANISTIC BURDEN OF INTOLERANCE TO FIRST OR SECOND TKIS (SHIFT) STUDY IN THE US (Wei D) • PS1596: CLINICAL FEATURES AND T CELL REPERTOIRE OF CHRONIC MYELOID LEUKEMIA PATIENTS WHO ATTEMPT DISCONTINUATION OF TYROSINE KINASE INHIBITORS: THE ISAC-TFR STUDY (Fujita M) • PS1597: DEVELOPMENT OF A NOVEL SCORING TOOL TO PREDICT OPTIMAL RESPONSE IN CHRONIC MYELOID LEUKEMIA FOR IMPROVING TREATMENT EFFICACY BEYOND CURRENT RISK CLASSIFICATIONS (Suzuki K) • PS1598: IMPACT OF PONATINIB TREATMENT ON PREGNANCY OUTCOMES (Abruzzese E) • PS1599: ANALYSIS OF FACTORS INFLUENCING TREATMENT-FREE REMISSION OUTCOMES AFTER IMATINIB DISCONTINUATION IN PAEDIATRIC CHRONIC MYELOID LEUKEMIA (Zhang Y) • PF593: EXPLORATORY ANALYSIS OF PREVALENT ADDITIONAL GENOMIC ALTERATIONS (AGAS) AT BASELINE (BL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM ASC4FIRST (Hughes T) • PF594: THE STRATEGY OF ASCIMINIB MANAGEMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN TRANSPLANT PRACTICE (Vlasova Y) • PF595: INTERIM ANALYSIS (IA) RESULTS FROM ASC2ESCALATE SUPPORT ASCIMINIB (ASC) AS A TREATMENT (TX) OPTION IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) AFTER 1 TYROSINE KINASE INHIBITOR (TKI) (Atallah E) • PF596: NEW PEDIATRIC FORMULATION OF ASCIMINIB IN CHILDREN WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: SECOND INTERIM ANALYSIS OF PHARMACOKINETICS, SAFETY AND GROWTH DATA FROM THE ASC4KIDS STUDY (Metzler M)

Time slots	Sessions
	<ul style="list-style-type: none"> • PF597: ASCIMINIB AFTER ONE PRIOR TYROSINE KINASE INHIBITOR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA - A PHYSICIAN PANEL-BASED CHART REVIEW STUDY IN THE UNITED STATES (Wei D) • PF598: DNMT3A, GATA2 AND SETBP1 VARIANT STATUS IN BONE MARROW MONONUCLEAR CELLS IS PREDICTIVE OF TREATMENT-FREE REMISSION IN CML PATIENTS FROM THE DESTINY TRIAL (Patterson S) • PF599: THE EUTOS LONG-TERM SURVIVAL SCORE PREDICTS FAILURE-FREE SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS IN THE ERA OF SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG-JSH CML STUDY (Takagi F) • PF600: NEW CHINESE SCORE FOR PREDICTING OUTCOMES TO FIRST-LINE CML THERAPY IS NOT SUPERIOR TO ELTS WHEN TESTED IN A EUROPEAN POPULATION WITH AN OLDER MEDIAN AGE: A STUDY FROM THE ITALIAN CML CAMPUS NETWORK (Rosso T) • PF602: INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEALS THE CLINICAL HETEROGENEITY OF NEWLY-DIAGNOSED ACCELERATED-PHASE CHRONIC MYELOID LEUKEMIA (Bao M) • PF603: SUSTAINED IMPAIRMENT OF KIDNEY FUNCTION IN PATIENTS WITH PH+ CML TREATED WITH IMATINIB (John MV) • PF604: TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DE NOVO ACCELERATED-PHASE AND/OR TYROSINE KINASE-INHIBITOR FAILURE: A RETROSPECTIVE MULTICENTER STUDY (Yuan M) • PF605: HLA DIVERSITY IS ASSOCIATED WITH TREATMENT RESPONSE AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (Toulemonde C) • PF606: BCR::ABL1 KINETICS IN PERIPHERAL BLOOD DURING DOSE DE-ESCALATION PHASE ARE PREDICTIVE OF TFR SUCCESS: A SUB-STUDY OF THE DESTINY CLINICAL TRIAL (Patterson S)
For publication only	
Chronic myeloid leukemia – Biology & Translational	<ul style="list-style-type: none"> • PB2681: DYNAMIC INTERVAL DRUG DOSING USING MICROFLUIDIC CELL ARRAY TO INVESTIGATE CHRONIC MYELOID LEUKEMIA CELL-DRUG RESPONSE (Kim T) • PB2682: CORRELATION BETWEEN CIRCULATING CD26+ LEUKEMIC STEM CELLS AND BCR::ABL1+ EXTRACELLULAR VESICLES IN CHRONIC MYELOID LEUKEMIA PATIENTS: A

Time slots	Sessions
research	<p>PRELIMINARY STUDY (Bernardi S)</p> <ul style="list-style-type: none"> • PB2683: METABOLIC REPROGRAMMING IN DRUG RESISTANCE: IN VITRO STUDIES IN MODELS OF CHRONIC MYELOID LEUKEMIA AND MULTIPLE MYELOMA (Sarmiento-Ribeiro AB) • PB2684: QUANTIFICATION OF ATYPICAL BCR::ABL1 TRANSCRIPTS BY DIGITAL PCR: AN EUTOS PROJECT (Danzero A) • PB2685: EXTRACELLULAR VESICLES MOLECULAR FINGERPRINTING WITH FOURIER TRANSFORM INFRARED SPECTROSCOPY: NOVEL APPROACH FOR MONITORING CHRONIC MYELOID LEUKEMIA TREATMENTS (Mutti S) • PB2686: THE GAB2 NETWORK IN ACTION: UNVEILING GAB2, GRB2, PIK3R1, AND LYN IN CHRONIC MYELOID LEUKEMIA (Kusma Wosniaka D) • PB2687: TYROSINE KINASE INHIBITOR THERAPY ENHANCES STEM CELLS PROFILE AND MAY CONTRIBUTE TO SURVIVAL OF CHRONIC MYELOID LEUKEMIA STEM CELLS (Panuzzo C) • PB2688: REDEFINING CML MONITORING: HIGH-PRECISION DIGITAL PCR FOR BCR::ABL1 QUANTIFICATION (Kim YH) • PB2689: DECODING INTERMODEL HETEROGENEITY IN CHRONIC MYELOID LEUKEMIA: INSIGHTS FROM IN VITRO EXTRACELLULAR VESICLES' RELEASE (Cavalleri A) • PB2690: CHRONIC MYELOID LEUKEMIA MONITORING EXPERIENCE IN ECUADOR, SOLCA - GUAYAQUIL (2015-2024) (Ruiz-Cabezas JC) • PB2691: CURCUMIN POTENTIATES THE CYTOTOXIC EFFICACY OF IBRUTINIB IN TP53-MUTATED CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS (Guo X) • PB2692: NAVIGATING THE LANDSCAPE OF IMATINIB FAILURE IN EASTERN INDIAN CML COHORT: SPOTLIGHT ON NOVEL BCR-ABL1 MUTATIONS, CLINICAL OUTCOMES AND THERAPY SWITCH (Dey S) • PB2693: CHALLENGES IN TREATING CML PATIENTS IN LOW INCOME COUNTRIES: A SINGLE CENTRE EXPERIENCE (Suse N) • PB2694: MAPPING THE METABOLIC RESPONSE OF MALIGNANT HEMATOPOIETIC CELLS TO CHEMOTHERAPY (Bucakci A) • PB2695: FALSELY NEGATIVE TARGETED NEXT GENERATION SEQUENCING IN CHRONIC MYELOID LEUKEMIA (Aldhafeeri D) • PB2696: ENHANCING CHRONIC MYELOID LEUKEMIA SURVEILLANCE: DIGITAL PCR VS RT-QPCR FOR BCR-ABL1 QUANTIFICATION' (Ibrahim RM) • PB2697: ASSESSING MOLECULAR RESPONSE DEPTH IN PH+ CML PATIENTS: THE ROLE OF

Time slots	Sessions
	<p>REVERSE TRANSCRIPTASE ENZYME SELECTION (Stević MS)</p> <ul style="list-style-type: none"> • PB2698: ASSESSMENT OF T315I MUTATION PREVALENCE AMONG TYROSINE KINASE INHIBITORS-RESISTANT PH+ LEUKEMIA PATIENTS, A TUNISIAN RETROSPECTIVE STUDY (Touaiti H)
Chronic myeloid leukemia - Clinical	<ul style="list-style-type: none"> • P2699: REAL-WORLD TREATMENT PATTERNS OF TYROSINE KINASE INHIBITORS IN KOREAN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (Lee SE) • PB2700: SECOND TREATMENT FREE REMISSION AFTER COMBINATION THERAPY WITH RUXOLITINIB PLUS TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) (Sweet K) • PB2701: CLINICAL FEATURES AND GENETIC ABNORMALITIES PREDICT OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE ACCELERATED-PHASE RECEIVING OLVEREMBATINIB THERAPY: A RETROSPECTIVE MULTICENTER STUDY (Yuan M) • PB2702: DE-ESCALATION AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS RECEIVING SALVAGE THERAPY FOR RESISTANCE, WARNING OR LACK OF DEEP MOLECULAR RESPONSE (Rea D) • PB2703: DISCONTINUING TKIS IN CML PATIENTS LACKING DEEP MOLECULAR RESPONSE: RISK OR OPPORTUNITY? AN EXPLORATORY STUDY FROM THE ITALY-TFR REGISTRY (Bonumo V) • PB2705: ASCIMINIB AS INITIAL THERAPY WITH ADDITION OF LOWER DOSE TYROSINE KINASE INHIBITORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO DO NOT ACHIEVE OPTIMAL RESPONSE OR A DEEP MOLECULAR REMISSION (ALERT CML): A STUDY FROM THE H JEAN KHOURY CURE CML CONSORTIUM (HJKC3) (Mauro M) • PB2706: EFFICACY AND SAFETY OF FLUMATINIB IN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE, MULTICENTER, REAL-WORLD STUDY (Zhang Y) • P2727: UPDATED PREVALENCE OF CHRONIC MYELOID LEUKAEMIA IN LOMBARDY IN 2024: A MODEL WITH GLOBAL IMPLICATIONS (Colombo F) • PB2708: APPLICABILITY OF THE HFA-ICOS SCORE AS A CARDIOVASCULAR RISK ASSESSMENT TOOL IN CML PATIENTS (Díaz AS) • PB2709: REAL-WORLD OUTCOMES OF ASCIMINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA RESISTANT OR INTOLERANT TO TYROSINE KINASE INHIBITORS:

Time slots	Sessions
	<p>A MULTICENTRE CHART REVIEW STUDY IN THE UK (Choy A)</p> <ul style="list-style-type: none"> • PB2710: COMPARATIVE EFFECTS OF THE ALLOSTERIC INHIBITOR ASCIMINIB AND ATP-COMPETITIVE TYROSINE KINASE INHIBITORS ON BONE METABOLISM (Sembill S) • PB2711: ASSESSMENT OF DRUG-DRUG INTERACTION POTENTIAL BETWEEN ASCIMINIB AND ATORVASTATIN IN HEALTHY PARTICIPANTS (Hoch M) • PB2712: PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO HAVE NOT ACHIEVED MAJOR MOLECULAR RESPONSE HAD SIGNIFICANTLY INCREASED RISK OF DISEASE PROGRESSION WHEN RECEIVING DE-ESCALATION TYROSINE KINASE INHIBITORS (TKIS) TREATMENT (Liu B) • PF2713: SEX AFFECTS BOSUTINIB DOSING, TOLERABILITY, AND EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: POST HOC ANALYSIS OF THE BODO STUDY (Isfort S) • PF2714: A REAL-WORLD STUDY OF OLVEREMBATINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA FROM CHINA: A SINGLE-CENTER RETROSPECTIVE STUDY (Dong T) • PF2715: THE OUTCOMES OF CHRONIC MYELOID LEUKEMIA PATIENTS WITH SECONDARY MALIGNANCIES UPON TKI TREATMENT (Yingling Z) • PF2716: AN ANALYSIS OF 10 YEARS REAL-WORLD EXPERIENCE OF PONATINIB SAFETY PROFILE (Jabbour E) • PF2717: UNIQUE GENDER RELATED CHARACTERISTICS AND DIFFERENCES OF CML PATIENTS IN AZERBAIJAN (Shirinova A) • PF2718: ASC4REAL: HARNESSING AI TO REVEAL REAL-WORLD INSIGHTS ON THE EFFECTIVENESS OF ASCIMINIB IN PRE- AND POST-PONATINIB TREATED CML PATIENTS (Khanna A) • PF2720: HEALTH-RELATED QUALITY OF LIFE IMPROVED IN ADULTS WITH TYROSINE KINASE INHIBITOR-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA RECEIVING PONATINIB THERAPY (Yu L) • PF2721: PREDICTORS OF BLAST PHASE PROGRESSION IN CML: A RETROSPECTIVE ANALYSIS OF IMATINIB-TREATED PATIENTS (Chacon-Rangel LC) • PF2722: ACHIEVING TREATMENT FREE REMISSION IN CML PATIENTS TREATED WITH BOSUTINIB: DATA FROM THE ITALY-TFR REGISTRY (Fava C) • PF2723: MOLECULAR AND CLINICAL CHARACTERISTICS OF LYMPHOID BLAST CRISIS IN CHRONIC MYELOID LEUKEMIA (Patkowska P) • PF2724: CLINICAL PHARMACOKINETIC CHARACTERISTICS AND THE EXPOSURE-RESPONSE

Time slots	Sessions
	<p>RELATIONSHIP OF RADOTINIB IN ASIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Lee J)</p> <ul style="list-style-type: none"> • PF2726: PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA WITH CELLS HARBORING BCR::ABL DISCORDANTLY HIGHER THAN BLAST COUNT MAY REPRESENT DE NOVO BLAST PHASE OF CHRONIC MYELOID LEUKEMIA WITH SILENCED CHRONIC PHASE (Wang E) • PF2727: CLINICAL PHARMACOKINETIC CHARACTERISTICS AND THE EFFECT OF FOOD ON RADOTINIB IN HEALTHY VOLUNTEERS (Lee Y) • PF2728: ASCIMINIB AS SECOND-LINE THERAPY FOR CHRONIC MYELOID LEUKEMIA: CANADIAN AND INTERNATIONAL REAL-WORLD EXPERIENCE (Perusini MA) • PF2729: FOLLOW-UP OF ANTITYROSINE KINASE DISCONTINUATION IN THE CONTEXT OF TREATMENT-FREE REMISSION IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE (Moussa YB) • PB2730: EFFICACY AND SAFETY OF PEGYLATED INTERFERON α-2B IN COMBINATION THERAPY FOR TKI - INEFFECTIVE PATIENTS WITH CML-CP: A REAL-WORLD STUDY (Yang Y) • PF2731: TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA FOLLOWING THE SECOND DISCONTINUATION OF TYROSINE KINASE INHIBITORS (Zhang Y)